Case report: Dramatic response to alectinib in a lung adenosquamous carcinoma patient harbouring a novel CPE-ALK fusion

Lung Adenosquamous carcinoma (ASC) is a rare histological subtype of lung cancer accounting for 0.4%–4% of all lung cancers. ASC is generally considered to be an aggressive cancer with poor prognosis. There is no specific standard treatment for ASC, and current treatment of ASC is relied on the guid...

Descripción completa

Detalles Bibliográficos
Autores principales: Qin, Yanyan, Li, Fei, Tan, Yuan, Duan, Qianqian, Zhang, Qin
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2022
Materias:
Oncology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10111186/
https://www.ncbi.nlm.nih.gov/pubmed/37082099
http://dx.doi.org/10.3389/fonc.2022.998545

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10111186/
https://www.ncbi.nlm.nih.gov/pubmed/37082099
http://dx.doi.org/10.3389/fonc.2022.998545

Ejemplares similares